Home > Compound List > Compound details
51-06-9 molecular structure
click picture or here to close

4-amino-N-[2-(diethylamino)ethyl]benzamide

ChemBase ID: 907
Molecular Formular: C13H21N3O
Molecular Mass: 235.32534
Monoisotopic Mass: 235.16846231
SMILES and InChIs

SMILES:
O=C(NCCN(CC)CC)c1ccc(N)cc1
Canonical SMILES:
CCN(CCNC(=O)c1ccc(cc1)N)CC
InChI:
InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
InChIKey:
REQCZEXYDRLIBE-UHFFFAOYSA-N

Cite this record

CBID:907 http://www.chembase.cn/molecule-907.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
4-amino-N-[2-(diethylamino)ethyl]benzamide
IUPAC Traditional name
procainamide
Brand Name
Biocoryl
Novocainamid
Novocainamide
Novocaine Amide
Novocamid
Procainamide Hcl
Procaine Amide
Procamide
Procan
Procan Sr
Procanbid
Procapan
Promine
Pronestyl
Pronestyl-Sr
Synonyms
Procainamide
CAS Number
51-06-9
PubChem SID
160964370
46507313
PubChem CID
4913

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID
DrugBank DB01035 external link
PubChem 4913 external link
Data Source Data ID Price

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 15.7515745  H Acceptors
H Donor LogD (pH = 5.5) -2.27341 
LogD (pH = 7.4) -0.69723266  Log P 0.9508967 
Molar Refractivity 72.2498 cm3 Polarizability 26.875093 Å3
Polar Surface Area 58.36 Å2 Rotatable Bonds
Lipinski's Rule of Five true 
Log P 1.42  LOG S -1.89 
Solubility (Water) 3.02e+00 g/l 

PROPERTIES

PROPERTIES

Physical Property Bioassay(PubChem)
Solubility
5050 mg/L expand Show data source
Hydrophobicity(logP)
1.3 expand Show data source

DETAILS

DETAILS

DrugBank DrugBank
DrugBank - DB01035 external link
Item Information
Drug Groups approved
Description A derivative of procaine with less CNS action. [PubChem]
Indication For the treatment of life-threatening ventricular arrhythmias.
Pharmacology Procainamide is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Procainamide appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected.
Toxicity LD50=95 mg/kg (rat, IV); LD50=312 mg/kg (mouse, oral); LD50=103 mg/kg (mouse, IV); LD50=250 mg/kg (rabbit, IV)
Affected Organisms
Humans and other mammals
Biotransformation Hepatic
Absorption 75 to 95%
Half Life ~2.5-4.5 hours
Protein Binding 15 to 20%
Elimination Trace amounts may be excreted in the urine as free and conjugated p-aminobenzoic acid, 30 to 60 percent as unchanged PA, and 6 to 52 percent as the NAPA derivative.
Distribution * 2 L/kg
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    No data available
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle